We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

55 hedge funds and large institutions have $126M invested in CTI BioPharma Corp. (DE) Common Stock in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less capital invested

Capital invested by funds: $141M → $126M (-$14.6M)

11% less funds holding

Funds holding: 62 → 55 (-7)

24% less call options, than puts

Call options by funds: $443K | Put options by funds: $580K

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
55
Holders Change
-7
Holders Change %
-11.29%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
7
Increased
22
Reduced
11
Closed
13
Calls
$443K
Puts
$580K
Net Calls
-$137K
Net Calls Change
-$690K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$4.05M
2
Morgan Stanley
Morgan Stanley
New York
+$3.56M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$1.33M
4
Two Sigma Investments
Two Sigma Investments
New York
+$926K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$725K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$6.53M
2
CC
Caxton Corporation
New Jersey
-$4.03M
3
RPAM
Rhenman & Partners Asset Management
Sweden
-$966K
4
EI
EAM Investors
California
-$773K
5
Renaissance Technologies
Renaissance Technologies
New York
-$615K

CTIC Hedge Fund Activity: Q1 2021 in Review

55 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2021, worth a combined $126M — down 10% from $141M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CTIC and 7 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 22 added.

The largest buyer was Stonepine Capital Management, adding an estimated $4.05M. The largest seller was OrbiMed, cutting an estimated $6.53M.

  • 55 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2021, down from 62 in Q4 2020.
  • Funds reported $126M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2021, down 10% quarter-over-quarter.
  • 7 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2021 and 13 closed out, a net change of -6 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2021 was Stonepine Capital Management, an estimated $4.05M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2021 was OrbiMed, an estimated $6.53M sold.

Based on aggregated 13F filings for Q1 2021.